The $50m investment by Spain’s plasma product manufacturer Grifols SA in the US biomarker start-up Singulex Inc., announced May 31, has drawn attention to the Californian company’s progress in developing ever more sensitive bio-assays based on its Single Molecule Counting (SMC) technology, as well as to the global expansion plans of the world’s third-largest producer of plasma-derived products.
Barcelona-headquartered Grifols has taken a 20% stake in Singulex, joining an investor group that includes OrbiMed Advisors, Fisk Ventures LLC, the Japanese investment management company JAFCO and Prolog Ventures, in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?